Please login to the form below
TNBC
This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Trodelvy set for EU approval in breast cancer
This is good news for European patients with TNBC, the most aggressive form of the disease, which is more frequently diagnosed in younger and premenopausal women as well as being more ... Effective treatment options are extremely limited for patients
Latest news
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide, approximately 300, 000 cases every year. ... KEYNOTE-522 is the first large randomised phase 3 study to report a statistically
-
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... In addition to TNBC, datopotamab deruxtecan is in development for the treatment of a number of tumour types which express the cell-surface glycoprotein TROP2.
-
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1. ... with metastatic TNBC with PD-L1 tumour expression.
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
New trial data for Keytruda in triple-negative breast cancer
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
More from news
Approximately 5 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior
Cortellis Drugs to Watch in 2020 report
Deal Watch February 2017
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Valneva COVID-19 vaccine more effective than AZ
- Real-world data highlights flu vaccine efficacy
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- How do you define a biotech company?
- Attracting the best talent to build Lucid’s future
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
